News releases

Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump

-April 24, 2025

FDA clearance of this pump would pave the way for system integration with a CGM based on Abbott's most advanced CGM platform.

Read more >

New Simplera Sync™ sensor for the MiniMed™ 780G system now FDA approved

-April 18, 2025

Latest approval expands Medtronic CGM portfolio in the U.S.

Read more >

Voluntary recall notifying Medtronic insulin pump users of potential risks of shortened pump battery life

-October 4, 2024

Customers are being notified of the importance of checking built-in alerts and alarms for battery status and to contact Medtronic for pump replacement if affected by this issue.

Read more >

Medtronic announces FDA approval of Simplera™ CGM and global partnership with Abbott

-August 7, 2024

Medtronic Diabetes expands CGM offerings to meet more people where they are in their diabetes journey.

Read more >

New MiniMed™ 780G system data demonstrates ability to address persistent blood sugar challenges for people with type 1 diabetes

-June 21, 2024

With its advanced algorithm that provides auto corrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn phenomenon, and improved overnight sleep.

Read more >

MiniMed™ 780G system recognized among Fast Company’s 2024 World Changing Ideas

-May 20, 2024

"The recognition of the MiniMed™ 780G system as a World Changing Idea reflects our commitment to simplifying diabetes care and reducing the mental burden of this relentless disease," said Que Dallara, EVP and President, Medtronic Diabetes. "We're pleased to receive this honor and will keep working tirelessly to continue empowering individuals with the technology they need to thrive with type 1 diabetes."

Read more >

New real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management

-March 9, 2024

The data was presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy. These results build on the 3-year data published in Diabetes Technology & Therapeutics showing over 100,000 real-world users achieving a Time in Range (TIR) of 78% with the use of recommended optimal settings, outperforming international targets of 70% TIR.

Read more >

Medtronic Diabetes partners with actress Alexandra Park to share her journey with diabetes technology and how it’s helped her find peace of mind

-January 31, 2024

Actress, writer and producer Alexandra Park, best known for her role on The Royals and Australian series Home and Away, is partnering with Medtronic Diabetes to help others living with type 1 diabetes learn more about advanced technologies that can help make life with the condition easier.

Read more >

Medtronic real-world evidence demonstrates consistent results of the MiniMed™ 780G regardless of demographic or cultural differences

-October 5, 2023

Data shows the successful performance of the AID algorithm under substantial changes to daily routines and lifestyle, including during Ramadan.

Read more >

The MiniMed™ 780G system with Meal Detection™ technology^* now available to Medicare beneficiaries

-July 6, 2023

Orders will be processed immediately and shipments will start in the coming weeks.

Read more >

InPen™ Smart Insulin Pen data shows the system’s unique reminders improve treatment outcomes for those using multiple daily injections

-June 23, 2023

Results show that the use of InPen resulted in an increase in Time in Range among those in the studies.

Read more >

Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users

-June 23, 2023

DUBLIN and SAN DIEGO, June 23, 2023 / PRNewswire / Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system. These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting glycemic goals, and individuals using a simplified meal announcement leveraging fixed carbohydrate amounts instead of exact carb calculations, found that the proprietary Meal Detection™ technology supported Time in Range outcomes that exceed consensus guidelines of 70 percent.

Read more >

Medtronic Diabetes resolves warning letter, clearing path for future innovations

-April 25, 2023

DUBLIN, April 25, 2023 / PRNewswire / Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) lifted the warning letter received at the company's Diabetes headquarters in Northridge, California, in December 2021. This follows on the heels of last week's FDA approval of the MiniMed™ 780G system, the world's first and only automated insulin delivery system with meal detection technology^* that provides automatic adjustments and corrections^† to glucose levels every 5 minutes.^§

Read more >

FDA Approves Medtronic MiniMed™ 780G System - World's First Insulin Pump with Meal Detection Technology* Featuring 5-Minute Auto Corrections†§

-April 21, 2023

DUBLIN, April 21, 2023 / PRNewswire / Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 780G system with the Guardian™ 4 sensor requiring no fingersticks while in SmartGuard™ technology^‡. This milestone marks the approval of the only system with meal detection technology^* that provides automatic adjustments and corrections^† to sugar levels every 5 minutes^§. The system provides insulin to help account for when users occasionally forget to bolus or underestimates the number of carbs in their meal.

Read more >

Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in U.S.

-November 15, 2022

DUBLIN, Nov. 15, 2022 /PRNewswire/ – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. launch of Medtronic Extended infusion set, the first and only infusion set labelled for up to 7-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days.

Read more >

Medtronic leverages data science to launch first-of-its-kind personalized insights program for people living with diabetes

-October 18, 2022

DUBLIN, Oct. 18, 2022 /PRNewswire/ – Medtronic plc (NYSE:MDT), the global leader in medical technology, is introducing a new program called My Insights exclusively made for individuals using the MiniMed™ 770G system. Using an individual's data, My Insights relies on the power of data science to provide personalized tips, trends, and reminders that customers can use to help with their diabetes management goals. The My Insights personalized recommendations are shared via a monthly email with educational content that is most relevant based on what an individual may currently be experiencing.

Read more >

CMS expands diabetes Medicare coverage to include CGMs that integrate with Medtronic insulin pumps

-December 22, 2021

Medicare coverage for Medtronic customers will be available 60 days after official publication

DUBLIN, Dec. 22, 2021 /PRNewswire/ – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) will expand Medicare coverage for all types of continuous glucose monitors (CGMs), including adjunctive and non-adjunctive CGMs. This includes CGMs that integrate with Medtronic insulin pumps. The proposed rule was finalized on December 21, 2021 and will be effective starting 60 days after official publication.

Read more >